Alzheimer's Disease News and Research

RSS
Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.
‘Still Alice’ movie portrays young onset dementia

‘Still Alice’ movie portrays young onset dementia

People who exhibit resistance to aspirin may be at risk of more severe strokes

People who exhibit resistance to aspirin may be at risk of more severe strokes

LSU Health New Orleans finalizes deal with CB BioSciences

LSU Health New Orleans finalizes deal with CB BioSciences

Neuronetrix announces FDA approval of COGNISION System for clinical use

Neuronetrix announces FDA approval of COGNISION System for clinical use

Virus that causes chicken pox and shingles linked to giant cell arteritis

Virus that causes chicken pox and shingles linked to giant cell arteritis

Women with multiple sclerosis may have lower levels of antioxidant, anti-inflammatory nutrients

Women with multiple sclerosis may have lower levels of antioxidant, anti-inflammatory nutrients

New study links chicken pox and shingles virus to giant cell arteritis in elderly

New study links chicken pox and shingles virus to giant cell arteritis in elderly

Researchers assemble comprehensive map of human epigenome

Researchers assemble comprehensive map of human epigenome

Epigenome may hold promise for conquering diseases

Epigenome may hold promise for conquering diseases

New treatment may bring hope for people suffering from muscle cramps

New treatment may bring hope for people suffering from muscle cramps

First comprehensive maps and analyses of human epigenomes revealed

First comprehensive maps and analyses of human epigenomes revealed

Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis provides overview of standalone global pharmaceutical development pipeline

Scientists identify role of tau-associated MAPT gene in development of Alzheimer's disease

Scientists identify role of tau-associated MAPT gene in development of Alzheimer's disease

Researchers identify molecule that can block progression of Alzheimer's disease

Researchers identify molecule that can block progression of Alzheimer's disease

Trinity scientists reveal new marvel molecule that can block key process in inflammatory diseases

Trinity scientists reveal new marvel molecule that can block key process in inflammatory diseases

BHB compound produced during dieting blocks part of immune system involved in inflammatory disorders

BHB compound produced during dieting blocks part of immune system involved in inflammatory disorders

Study shows amyloid formation may link type 2 diabetes and Alzheimer disease

Study shows amyloid formation may link type 2 diabetes and Alzheimer disease

Study suggests introduction of specific NGF to prevent neuronal degradation in Alzheimer's patients

Study suggests introduction of specific NGF to prevent neuronal degradation in Alzheimer's patients

TSRI scientists discover novel mechanism involved in Alzheimer's, Parkinson's and ALS

TSRI scientists discover novel mechanism involved in Alzheimer's, Parkinson's and ALS

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.